Oncology Brothers: Practice-Changing Cancer Discussions
By Oncology Brothers
Listen to a podcast, please open Podcast Republic app. Available on Google Play Store and Apple App Store.
Image by Oncology Brothers
Category: Medicine
Open in Apple Podcasts
Open RSS feed
Open Website
Rate for this podcast
Subscribers: 8
Reviews: 0
Episodes: 100
Description
The Oncology Brothers Podcast, led by Drs. Rahul and Rohit Gosain, is dedicated to bridging the gap between academic cancer centers and community oncology in the ever-evolving field of hematology & oncology. With a mission to disseminate crucial information to the medical community, this oncology podcast is not for medical advice but rather serves as a beacon for physicians, nurses, trainees, and advanced practice providers (APPs) involved in the care of cancer patients.
Drs. Rahul and Rohit Gosain, both esteemed oncologists, bring a wealth of experience and expertise from their general community practice to these discussions. Through short and engaging interviews with world-renowned researchers, clinicians, hematologists, and oncologists, they present practice-changing data in a concise, bite-sized format.
Get the latest FDA approvals news, oncology conference highlights, and treatment algorithms in 25 minutes or less. Conversations center around common cancers you see in your clinic like breast cancer, prostate cancer, kidney cancer, bladder cancer, lung cancer, and GI cancers. With new indications and approvals, we talk about how to incorporate this data in your day to day clinical practice.
Each episode includes visual presentations so you can follow along within the podcast players and on YouTube @oncbrothers. These visual tools and algorithms will provide an outline on what is covered in each episode. Immediately apply the latest insights and advancements in your daily practice, ensuring the delivery of optimal cancer care to patients within your local communities.
If you want to navigate the complexities of your hematology & oncology practice and stay current, the Oncology Brothers Podcast offers invaluable insights and practical takeaways to enhance your professional journey and improve patient outcomes. For more information, please visit: www.oncbrothers.com, and connect with us on Twitter/X/Instagram/TikTok: @oncbrothers, or email us at info@oncbrothers.com
Privacy Policy: https://oncbrothers.com/privacy-policy
Terms & Conditions: https://oncbrothers.com/terms-and-conditions
| Episode | Date |
|---|---|
|
Managing Toxicities of Antibody Drug Conjugates (ADCs) in Lung Cancer – Dr. Jacob Sands
|
Dec 13, 2025 |
|
Managing Toxicities of PI3K & AKT Inhibitors in Breast Cancer – Drs. Emily Gallagher & Neil Iyengar
|
Dec 11, 2025 |
|
Challenging Cases of Iron Abnormalities, Anemia or Iron Overload - Dr. Marina Beltrami
|
Dec 04, 2025 |
|
FDA Approval of Epcoritamab-Rituximab-Lenalidomide for R/R Follicular Lymphoma – Dr. Gilles Salles
|
Dec 04, 2025 |
|
Challenging Cases in Second Line & Beyond Renal Cell Carcinoma (RCC) - Dr. David Braun
|
Nov 30, 2025 |
|
FDA Approval of Durvalumab with FLOT in Resectable Gastric & GEJ: MATTERHORN by Dr. Yelena Janjigian
|
Nov 26, 2025 |
|
Challenging Cases in Breast Cancer with CDK 4/6 Inhibitors – Drs. Sara Tolaney & Adam Brufsky
|
Nov 24, 2025 |
|
Challenging Cases in Non-Muscle Invasive Bladder Cancer (NMIBC) – Drs. Shilpa Gupta & Joshua Meeks
|
Nov 20, 2025 |
|
FDA Approval of Ziftomenib (KOMET-001) in NPM1 mut Acute Myeloid Leukemia (AML) – Dr. Eunice Wang
|
Nov 17, 2025 |
|
Managing Toxicities of ROS1 Inhibitors in Non-Small Cell Lung Cancer (NSCLC) – Dr. Estela Rodriguez
|
Nov 13, 2025 |
|
Managing Toxicities of Tyrosine Kinase Inhibitors (TKI) in CML - Drs. Onyee Chan & Fadi Haddad
|
Nov 10, 2025 |
|
Lung Cancer ESMO 2025 Highlights: MDT-BRIDGE, FLAURA2, SOHO-01, Beamion LUNG-1
|
Nov 06, 2025 |
|
GI Cancer ESMO 2025 Highlights: DYNAMIC-III, PEGASUS, STELLAR-303, MATTERHORN, FORTITUDE-101
|
Nov 03, 2025 |
|
Breast Cancer ESMO 2025 Highlights: MonarchE, NATALEE, VIKTORIA1, evERA, DESTINY, ASCENT, TROPION
|
Oct 30, 2025 |
|
Current Treatment Landscape of Ovarian Cancer with Dr. Sharyn Lewin
|
Oct 27, 2025 |
|
GU Cancer ESMO 2025 Highlights: PSMAddition, Capitello-281, Potomac, Keynote-905, IMVigor011
|
Oct 23, 2025 |
|
Challenging Cases with Metastatic EGFR Mutated Non-Small Cell Lung Cancer with Dr. Eric Singhi
|
Oct 20, 2025 |
|
Managing Toxicities of CDK4/6 Inhibitors in Hormone Positive Breast Cancer - Dr. Stephanie Graff
|
Oct 16, 2025 |
|
Treating and Managing Chronic Myeloid Leukemia (CML) in 2025: Dr. Jorge Cortes
|
Oct 13, 2025 |
|
How to Manage Thrombocytopenia (ITP, HIT, DIC, TTP) - Dr. Ronak Mistry
|
Oct 09, 2025 |
|
IMforte - Maintenance Lurbinectedin + Atezo FDA Approval for Extensive Small Cell Lung Cancer (SCLC)
|
Oct 06, 2025 |
|
Exploring the role of targeted radiopharmaceutical treatment in NETs
|
Oct 02, 2025 |
|
Challenging Cases of Venous Thromboembolism (VTE) - Drs. Jennifer Vaughn & Nicolas Gallastegui
|
Sep 29, 2025 |
|
How to Treat Cutaneous Melanoma in 2025 - Dr. Omid Hamid
|
Sep 25, 2025 |
|
Treatment Algorithm of Neuroendocrine Tumors (NET) in 2025 - Dr. Thor Halfdanarson
|
Sep 22, 2025 |
|
WCLC 2025 Highlights: FLAURA2, HARMONi, ALCHEMIST with Dr. Balazs Halmos
|
Sep 18, 2025 |
|
Treating and Managing Chronic Lymphocytic Leukemia (CLL) in 2025: Dr. Mazyar Shadman
|
Sep 11, 2025 |
|
Managing Side Effects of New Treatments for Small Cell Lung Cancer
|
Aug 29, 2025 |
|
FDA Approval of Zongertinib for HER2 Mutated Non-Small Cell Lung Cancer (NSCLC) - Dr. Joshua Sabari
|
Aug 25, 2025 |
|
Latest Clinical Data for First-line Maintenance and R/R Small-Cell Lung Cancer (SCLC)
|
Aug 21, 2025 |
|
FDA Approval of Datopotamab deruxtecan (Dato-DXd) in EGFR Mutated Lung Cancer - Dr. Jacob Sands
|
Aug 18, 2025 |
|
Diagnosis and Treatment of Myelofibrosis with Dr. Raajit Rampal: Testing, Treatment, Supportive care
|
Aug 11, 2025 |
|
Managing Toxicities of TKIs and HIF-2 inhibitor in Renal Cell Carcinoma (RCC)
|
Aug 07, 2025 |
|
Myeloproliferative Neoplasms (MPN) Treatment: Polycythema Vera (PV) & Essential Thrombocythemia (ET)
|
Aug 04, 2025 |
|
Latest Advances in Tumor-Agnostic Strategies for NTRK Fusion-Positive Cancer
|
Jul 31, 2025 |
|
Challenging Cases with Relapsed/Refractory FLT3+ Acute Myeloid Leukemia (AML)
|
Jul 28, 2025 |
|
Treating Acute Myeloid Leukemia in 2025 - Induction, Consolidation, Transplant, Target Therapies
|
Jul 24, 2025 |
|
Challenging Cases with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
|
Jul 21, 2025 |
|
How to Treat Diffuse Large B-Cell Lymphoma (DLBCL) in 2025
|
Jul 17, 2025 |
|
How to Treat Early Stage Non-Small Cell Lung Cancer in 2025
|
Jul 10, 2025 |
|
ASCO 2025 - GU Cancer Highlights: KEYNOTE-564, AMPLITUDE, ARANOTE, NIAGARA
|
Jul 04, 2025 |
|
FDA Approval of Telisotuzumab (Teliso-V) in c-MET Overexpression - LUMINOSITY trial
|
Jun 27, 2025 |
|
ASCO 2025 - Breast Cancer Highlights: INAVO120, SERENA-6, VERITAC-2, DESTINY-Breast09, ASCENT-04
|
Jun 20, 2025 |
|
ASCO 2025 - GI Cancer Highlights: DYNAMIC III, ATOMIC, BREAKWATER, MATTERHORN, DESTINY Gastric04
|
Jun 14, 2025 |
|
ASCO 2025 Lung Cancer Highlights: CheckMate 816, ToD, NeoADAURA, IMforte, DeLLphi 304
|
Jun 07, 2025 |
|
Nivolumab plus Ipilimumab in Microsatellite-Instability–High (MSI-H) Metastatic Colorectal Cancer
|
May 26, 2025 |
|
Managing Toxicities of EGFR Inhibitors: Afatinib, Amivantamab-Lazertinib, Osimertinib
|
May 21, 2025 |
|
How to treat Small Cell Lung Cancer in 2025
|
May 19, 2025 |
|
Treatment of Metastatic Non-Small Cell Lung Cancer With Targeted Mutations
|
May 15, 2025 |
|
How to Treat Metastatic Non-Small Cell Lung Cancer (NSCLC) Without Targeted Mutations
|
May 12, 2025 |
|
Managing Side Effects of HER2 Targeted Therapy - Zanidatamab & Trastuzumab deruxtecan (T-DXd)
|
May 08, 2025 |
|
Perioperative Durvalumab FDA Approval New Standard for Muscle Invasive Bladder Cancer
|
May 05, 2025 |
|
Treatment Options for HER2 Positive Biliary Tract Cancers
|
May 01, 2025 |
|
The HER2 Diagnostic and Treatment Landscape in NSCLC
|
Apr 29, 2025 |
|
Overview of Biliary Tract Cancer & Importance of Targeted Therapies
|
Apr 24, 2025 |
|
What does it mean to be HER2 Positive in Lung Cancer
|
Apr 21, 2025 |
|
European Lung Cancer Conference (ELCC) 2025 Highlights: KEYNOTE-799, LAURA, MARIPOSA, KRYSTAL-7
|
Apr 14, 2025 |
|
FDA Approval of Cabozantinib - CABINET in pNET and epNET
|
Apr 10, 2025 |
|
How to Manage & Treat Pancreatic Cancer
|
Apr 07, 2025 |
|
How to Treat Upper Gastrointestinal Cancers in 2025 - Treatment Algorithm
|
Mar 31, 2025 |
|
ToxCheck: Managing Side Effects of Pancreatic Cancer Treatment
|
Mar 27, 2025 |
|
Prostate Cancer Management from Early Stage to Advanced Metastatic Disease - Dr. Alan Bryce
|
Mar 24, 2025 |
|
How to Treat Renal Cell Carcinoma (RCC) using a Treatment Algorithm with Dr. Katy Beckermann
|
Mar 17, 2025 |
|
How to Treat Bladder Cancer in 2025 with Dr. Joaquim Bellmunt
|
Mar 10, 2025 |
|
FDA Approval of Tislelizumab - RATIONALE 305 and 306 in Upper GI Cancers
|
Mar 06, 2025 |
|
GU ASCO 2025 Highlights - TALAPRO-2, NIAGARA, CheckMate-9ER, TiNivo-2
|
Mar 03, 2025 |
|
How to Treat Hormone Receptor Positive Cancer - Latest Advancements and Current Standard of Care in 2025
|
Feb 24, 2025 |
|
FDA Approval of Zolbetuximab SPOTLIGHT / GLOW study - Upper GI Cancer with Claudin 18.2 Mutation
|
Feb 21, 2025 |
|
How to Treat HER2+ Breast Cancer - Discussion with Dr. Sarah Sammons
|
Feb 17, 2025 |
|
How to Treat Triple Negative Breast Cancer - Discussion with Dr. Virginia Kaklamani
|
Feb 10, 2025 |
|
GI ASCO 2025 Highlights - BREAKWATER, CheckMate-8HW, ALASCCA, STARTER-NET
|
Feb 03, 2025 |
|
FDA Approval of Subcutaneous Nivolumab CheckMate-67T - Subcutaneous Nivo vs. Intravenous (IV) Nivo
|
Jan 31, 2025 |
|
Intermediate HCC – the evolving role of Immunotherapy with Multimodality approaches
|
Jan 27, 2025 |
|
Managing Side Effects of Anti-VEGF Bevacizumab & Anti-EGFR Cetuximab and Panitumumab
|
Jan 22, 2025 |
|
ASH Lymphoma 2024 Highlights - POLARIX Update, inMIND, TRIANGLE, ENRICH with Dr. Pallawi Torka
|
Jan 21, 2025 |
|
SABCS 2024 Highlights - DESTINY-Breast06, DESTINY-Breast12, PATINA with Dr. Sara Tolaney
|
Jan 17, 2025 |
|
SABCS 2024 Highlights - EUROPA, TAILORx, PADMA, EMBER-3 with Dr. Jame Abraham
|
Jan 15, 2025 |
|
Intermediate Hepatocellular Carcinoma (HCC) – Treatment Options & Strategies
|
Jan 13, 2025 |
|
SABCS 2024 Highlights - INSEMA, KEYNOTE-522, OlympiA
|
Jan 09, 2025 |
|
Multiple Myeloma ASH 2024 Highlights with Dr. Robert Orlowski
|
Jan 07, 2025 |
|
FDA Approval of Zanidatamab - HERIZON-BTC-01 Discussion with Dr. Shubham Pant
|
Jan 02, 2025 |
|
ASH 2024 CLL Highlights - SEQUOIA, AMPLIFY, CELESTIAL, Role of CAR-T Cell Therapy
|
Dec 26, 2024 |
|
CAR-T Toxicity Check: From Approval to Practice, Managing Side Effects of CAR-T Therapy
|
Dec 21, 2024 |
|
Leukemia ASH 2024 Highlights - Menin Inhibitors, CPX 351 vs 7+3, Venetoclax Based Regimens
|
Dec 19, 2024 |
|
2nd line treatment in advanced HCC and when to switch
|
Dec 13, 2024 |
|
From Approval to Practice: Managing Side Effects of Antibody Drug Conjugates (ADC) in Cancer
|
Dec 02, 2024 |
|
The use of Immunotherapy in unresectable Hepatocellular Carcinoma (HCC)
|
Nov 28, 2024 |
|
INAVO120 - FDA Approval of Inavolisib in Endocrine-Resistant, PIK3CA-mut, HR+ Advanced Breast Cancer
|
Nov 25, 2024 |
|
How to Approach and Treat Pancreatic Cancer
|
Nov 21, 2024 |
|
Understanding the Impact of Nutrition & Exercise on Cancer Outcomes
|
Nov 18, 2024 |
|
How to Diagnose, Treat, and Follow Neuroendocrine Tumors (NETs)
|
Nov 14, 2024 |
|
Palliative Care Management in Cancer
|
Nov 08, 2024 |
|
How to Approach to Ovarian Cancer from Community Oncology Perspective
|
Oct 31, 2024 |
|
How to Approach to Endometrial Cancer from Community Oncology Perspective
|
Oct 24, 2024 |
|
DeLLphi-301 - FDA Approval of Tarlatamab in Patients w/ Prev Treated Small Cell Lung Cancer (SCLC)
|
Oct 22, 2024 |
|
AEGEAN Study - FDA Approval of Durvalumab in Resectable Non-Small Cell Lung Cancer
|
Oct 20, 2024 |
|
Lung Cancer ESMO 2024 Highlights: Key Studies Discussed LAURA, MARIPOSA, MARIPOSA-2, ADRIATIC
|
Oct 17, 2024 |
|
AGAVE-201 Study - FDA Approval of Axatilimab for Chronic Graft-versus-Host Disease (cGVHD)
|
Oct 15, 2024 |
|
How to Approach to Acute Myeloid Leukemia (AML) from Community Oncology Perspective
|
Oct 13, 2024 |
|
GI Cancer ESMO 2024 Highlights: Key Studies Discussed LEAP-012, KEYNOTE-811, POD1UM-303, NICHE-2
|
Oct 10, 2024 |